Legacy Inmagene

Inmagene Biopharmaceuticals is a clinical-stage biotechnology company dedicated to developing innovative therapies for immunological and inflammatory diseases. The company utilizes a "borderless innovation" model, combining internal R&D with strategic global partnerships to build a robust pipeline of small molecules and biologics. Its lead programs include IMG-007, an OX40L-targeting antibody for atopic dermatitis, and IMG-004, a non-covalent BTK inhibitor. With operations in China and the United States, Inmagene focuses on high-unmet-need indications such as psoriasis, hidradenitis suppurativa, and various arthritic conditions.